On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted narrowly to recommend six peptides—BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon—for the agency's 503A Bulks List, overruling career scientists who had advised against all seven compounds under review (AJMC's coverage of the panel vote). The recommendation targets human compounding pharmacies. It says nothing about animals. Yet within weeks, dog owners were administering BPC-157 and TB-500 by subcutaneous injection using dosing figures circulated in pet-care forums, with no published canine trial and no FDA-approved veterinary product behind either compound.
An Advisory Vote, Not a Rule
Scott Brunner, CEO of the Alliance for Pharmacy Compounding, noted after the meeting that FDA must formally adopt the advisers' recommendations before the peptides may be legally compounded (Bipc's regulatory analysis). PCAC serves an advisory role. The agency has not finalized the 503A Bulks List additions, and the votes do not constitute approval: no validated indications, no standardized dosing, and no established safety data attach to any of the six compounds.
For veterinary use the regulatory gap is wider. No company has submitted an FDA animal drug application for BPC-157 or TB-500. No published randomized controlled trial evaluates either peptide in dogs. The FDA has not approved these synthetic compounds for any indication in any species (Cedars-Sinai's peptide safety overview).
Dosing Figures Without a Canine Standard
No veterinary pharmacology body has issued dosing guidelines for BPC-157 or TB-500 in dogs. The figures circulating among pet owners—5 to 10 micrograms per kilogram daily for BPC-157, 0.1 to 0.25 milligrams per kilogram weekly for TB-500—appear in informal peptide guides for pets and in community threads that pair the two compounds under the wolverine stack label borrowed from human fitness culture. Rodent wound-healing data and a preclinical safety study in mice, rats, rabbits, and dogs inform the biological rationale, but no controlled canine trial has confirmed a therapeutic dose or a toxicity threshold.
BPC-157 is typically administered as a small subcutaneous injection or oral capsule in short cycles around an injury, with amounts referenced in the microgram-per-kilogram range. TB-500, a synthetic fragment of thymosin beta-4, targets actin sequestration and cell migration in tendon and ligament tissue. Neither compound carries a labeled canine indication.
Angiogenesis Risk and an Unverified Supply Chain
Both peptides promote angiogenesis in animal models, the mechanism through which they theoretically accelerate tissue repair. That same mechanism could support an existing or undiagnosed tumor. Older dogs—the population most likely to receive these injections for arthritis or soft-tissue decline—are also the population most likely to harbor undiagnosed masses. No veterinary oncology body has issued screening guidance tied to peptide administration.
Medical experts have raised concerns about serious immune or allergic responses to experimental, unregulated injectable peptides (the Sun Sentinel's reporting on peptide health risks). The FDA's own briefing materials flagged potential immunogenicity of BPC-157 acetate in injectable form, citing aggregation risk and peptide-related impurities.
In the United States, BPC-157 and TB-500 are classified as research-use-only chemicals. Products sold under that label carry no sterility guarantee, no verified concentration, and no endotoxin testing a dog owner can confirm before drawing a dose. Many originate from unregulated labs, often in China, and enter the U.S. market through online vendors. HHS Secretary Robert F. Kennedy Jr. has signaled interest in expediting peptide access, but experts say the timeline and mechanism remain unclear. Until FDA finalizes or rejects the PCAC recommendation, the compounds remain restricted for human compounding and entirely outside any veterinary approval framework.
Related Peptides Agora coverage examines what are peptides, and peptides for healing.
